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Epilepsy is one of the most common 
serious brain disorders worldwide. Un-
fortunately, mortality rates are consider-
ably higher in people with epilepsy than 
would be expected in a healthy population 
and sudden unexpected death in epilepsy 
(SUDEP) is the most frequent epilepsy-re-
lated category of death1,2.
The definition of sudden death in ep-
ilepsy differs from that of sudden death 
in general, as the latter includes deaths 
with and without an identified patho-
logic cause2. Besides, the lack of autop-
sy findings and the rarely witnessed cas-
es of SUDEP pose difficulties with regard 
to definitions of SUDEP. In general terms, 
SUDEP is defined by precise criteria that 
were approved in 1997 by an expert pan-
el and is designed as sudden, unexpected, 
witnessed or unwitnessed, nontraumatic 
and nondrowning deaths in patients with 
epilepsy, with or without evidence of a sei-
zure and excluding documented status ep-
ilepticus, in which post mortem examina-
tion does not reveal a toxicological or ana-
tomical cause of death3. Currently, SUDEP 
is responsible for 7.5% to 17% of all deaths 
in epilepsy and has an incidence among 
adults between 1:500 and 1:1,000 patient-
years4. In parallel, a number of associated 
factors for SUDEP have been reported but 
the results are not wholly consistent be-
tween studies. Thus, the main risk factors 
evaluated until now include refractoriness 
of the epileptic condition, presence of gen-
eralized tonic-clonic seizures, antiepileptic 
medication (polytherapy with antiepileptic 
drugs), young age, duration of the seizure 
disorder, early onset of epilepsy and winter 
temperatures5,6. Although different mech-
anisms may play separate roles in different 
cases5, the two major domains of potential 
mechanisms of SUDEP are autonomic, i.e., 
respiratory, and cardiovascular7. Accord-
ing to the latter, a significant body of lit-
erature suggests that SUDEP has a poten-
tial cardiac mechanism, due to repetitive 
cardiac damage during seizures and due to 
arrhythmia during seizures, possibly trig-
gered by apnea and/or cerebral autonomic 
imbalance8.
From an experimental perspective, al-
though much has been learned from an-
imal studies about structural, chemical, 
and physiological changes that contribute 
to seizures and epilepsy, the development 
of experimental preparations that closely 
model the human SUDEP phenomenon is 
essential, since could provide vital informa-
tion to aid elucidation of the pathogenetic 
mechanisms of SUDEP and stimulate in-
vestigation into possible therapeutic strat-
egies9. Following this line of reasoning, the 
experience of our research group makes 
us increasingly believe that some chronic 
models of temporal lobe epilepsy are im-
portant tools for the study of cardiovascu-
lar abnormalities in epilepsy and may even 
be relevant for the understanding of the 
SUDEP phenomenon. In 2005, we used the 
pilocarpine model in order to evaluate the 
heart rate from rats with epilepsy in vivo 
(ECG) and in an isolated ex vivo prepara-
tion (Langendorf preparation)10. In brief, 
we demonstrated a significant increase in 
baseline heart rate in vivo of animals with 
epilepsy (346±7 bpm) when compared with 
control group animals (307±9 bpm). Quite 
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interesting, we did not find differences in the isolated ex 
vivo situation (control animals: 175±7 bpm; animals with 
epilepsy: 176±6 bpm), suggesting that autonomic modu-
lation of the heart is changed in rats with epilepsy, which 
could explain the appearance and maintenance of an in-
creased basal heart rate in these animals10. Recently, we 
also analyzed heart rate in rats subjected to electrical kin-
dling of the amygdala11. The main purpose of our study 
was to evaluate changes in baseline heart rate and heart 
rate responses during stage 5 of kindling, which corre-
sponds to generalized seizures11. Briefly, the animals did 
not show significant differences in basal heart rate before 
and after electrode implantation. On the other hand, basal 
heart rate was higher during stage 5 of kindling, possibly 
resulting from sympathetic activation caused by the epi-
leptic condition. Furthermore, we also observed an intense 
bradycardia occurred at the beginning of seizure, followed 
by a rebound tachycardia. Interestingly, our results indi-
cated that the intensity of the tachycardia is direct related 
to the number of generalized seizures. Accordingly, these 
results allow us to describe that repeated generalized ton-
ic-clonic seizures directly affect sympathetic outflows11.
Returning to the clinical field, what are the best actu-
al proposals to minimize the occurrence of SUDEP? It is 
clear that SUDEP is mainly (but not exclusively) a prob-
lem for people with chronic uncontrolled epilepsy12, but 
our understanding of the best way to prevent it is still in-
complete. Thus, some strategies13 have been suggested 
that could be useful in reducing the risk of SUDEP: 
[1] Good control of seizures;
[2] Reduction of stress; 
[3] Participation in physical activity and sports; 
[4] Dietary management (e.g., omega-3 supplementation);
[5] Supervision at night;
[6] Family members’ knowledge of cardiopulmonary re-
suscitation (CPR) techniques and the basics of defi-
brillator use13.
On balance, as a complete understanding of all the 
risk factors, mechanisms, and specific methods to prevent 
SUDEP is yet to be obtained, caution is really prudent and 
necessary. In this sense, we are totally in agreement with 
previous studies14,15 that, if there is a reasonable chance of 
preventing SUDEP, it must be discussed with all patients 
with epilepsy at the highest risk of SUDEP. The physician 
can then explain possible strategies that people with epi-
lepsy and their families can take to try to reduce their risk 
of SUDEP. Furthermore, modern neuroscientists recog-
nizes that epilepsy-related mortality is a significant public 
health issue and should be closely monitored by govern-
ments that manage health care in their respective coun-
tries. Obviously, trying to solve these problems is never 
an easy task, The American Epilepsy Society and the Ep-
ilepsy Foundation Joint Task Force already initiated a task 
force to assess the state of knowledge (research directions, 
social, cultural and educational efforts) on SUDEP16. 
Finally, these stop/go decisions on SUDEP field devel-
oped recently by epileptologists is exactly what the new 
science called the translational research, which indicates 
the integration of the advancements in basic science with 
clinical trials, taking research from bench to bedside17.
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